Objectives COVID-19 outcomes in people with rheumatic diseases remain poorly understood. The aim was to examine demographic and clinical factors associated with COVID-19 hospitalisation status in people with rheumatic disease.
Methods Case series of individuals with rheumatic disease and COVID-19 from the COVID-19 Global Rheumatology Alliance registry: 24 March 2020 to 20 April 2020. Multivariable logistic regression was used to estimate ORs and 95% CIs of hospitalisation. Age, sex, smoking status, rheumatic disease diagnosis, comorbidities and rheumatic disease medications taken immediately prior to infection were analysed.
Results A total of 600 cases from 40 countries were included. Nearly half of the cases were hospitalised (277, 46%) and 55 (9%) died. In multivariable-adjusted models, prednisone dose ≥10 mg/day was associated with higher odds of hospitalisation (OR 2.05, 95% CI 1.06 to 3.96). Use of conventional disease-modifying antirheumatic drug (DMARD) alone or in combination with biologics/Janus Kinase inhibitors was not associated with hospitalisation (OR 1.23, 95% CI 0.70 to 2.17 and OR 0.74, 95% CI 0.37 to 1.46, respectively). Non-steroidal anti-inflammatory drug (NSAID) use was not associated with hospitalisation status (OR 0.64, 95% CI 0.39 to 1.06). Tumour necrosis factor inhibitor (anti-TNF) use was associated with a reduced odds of hospitalisation (OR 0.40, 95% CI 0.19 to 0.81), while no association with antimalarial use (OR 0.94, 95% CI 0.57 to 1.57) was observed.
Conclusions We found that glucocorticoid exposure of ≥10 mg/day is associated with a higher odds of hospitalisation and anti-TNF with a decreased odds of hospitalisation in patients with rheumatic disease. Neither exposure to DMARDs nor NSAIDs were associated with increased odds of hospitalisation.
- tumor necrosis factor inhibitors
- arthritis, rheumatoid
- lupus erythematosus, systemic
This article is made freely available for use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.https://bmj.com/coronavirus/usage
Statistics from Altmetric.com
Handling editor Josef S Smolen
Twitter @pedrommcmachado, @philipcrobinson
MG and KLH contributed equally.
JY, PMM and PCR contributed equally.
Correction notice This article has been corrected since it published Online First. The 'csDMARD only' line in table 3 has been corrected.
Collaborators on behalf of the COVID-19 Global Rheumatology Alliance (please see online appendix with full list of members).
Contributors MG, KLH, SA-A, LC, MID, LG, ZI, LJ, PK, SL-T, EFM, SR, GS, JS, AS, LT and KDW contributed to data collection, data quality control, data analysis and interpretation. They drafted, and revised, the manuscript critically for important intellectual content and gave final approval of the version to be published. SB, WC, RG, JSH, JWL, ES, PS and ZSW contributed to the acquisition, analysis and interpretation of the data. They drafted, and revised, the manuscript critically for important intellectual content and gave final approval of the version to be published. JY, PMM and PCR directed the work, designed the data collection methods and contributed to the analysis and interpretation of the data. They drafted, and revised, the manuscript critically for important intellectual content and gave final approval of the version to be published.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Disclaimer The views expressed here are those of the authors and participating members of the COVID-19 Global Rheumatology Alliance, and do not necessarily represent the views of the American College of Rheumatology (ACR), the European League Against Rheumatism (EULAR) or any other organisation. The views expressed are those of the authors and not necessarily those of the (UK) National Health Service (NHS), the National Institute for Health Research (NIHR) or the (UK) Department of Health.
Competing interests MG reports grants from National Institutes of Health, NIAMS, outside the submitted work. KLH reports she has received speaker’s fees from AbbVie and grant income from BMS, UCB and Pfizer, all unrelated to this manuscript. KLH is also supported by the NIHR Manchester Biomedical Research Centre. SA-A has nothing to disclose. LC has not received fees or personal grants from any laboratory, but her institute works by contract for laboratories among other institutions, such as AbbVie Spain, Eisai, Gebro Pharma, Merck Sharp & Dohme España, S.A., Novartis Farmaceutica, Pfizer, Roche Farma, Sanofi Aventis, Astellas Pharma, Actelion Pharmaceuticals España, Grünenthal GmbH and UCB Pharma. MD reports no competing interests related to this work. She is supported by grants from the National Institute of Health, Pfizer Independent Grants for Learning and Change, Genentech, Horizon Pharma. She has performed consultant work for Amgen, Novartis, Regeneron/Sanofi unrelated to this work. LG reports personal consultant fees from AbbVie, Biogen, Celgene, Janssen, Eli Lilly, Novartis, Pfizer, Sanofi-Aventis, UCB and grants from Eli Lilly, Mylan, Pfizer, all unrelated to this manuscript. EM reports that LPCDR received support for specific activities: grants from AbbVie, Novartis, Janssen-Cilag, Eli Lilly Portugal, Sanofi, Grünenthal S.A., MSD, Celgene, Medac, Pharmakern, GAfPA; grants and non-financial support from Pfizer; non-financial support from Grünenthal GmbH, outside the submitted work. GS reports no competing interests related to this work. Her work is supported by grants from the National Institutes of Health and Agency for Healthcare Research and Quality. She leads the Data Analytic Center for the American College of Rheumatology, which is unrelated to this work. AS reports grants from a consortium of 13 companies (among them AbbVie, BMS, Celltrion, Fresenius Kabi, Eli Lilly, Mylan, Hexal, MSD, Pfizer, Roche, Samsung, Sanofi-Aventis and UCB) supporting the German RABBIT register and personal fees from lectures for AbbVie, MSD, Roche, BMS, Pfizer, outside the submitted work. SB reports no competing interests related to this work. He reports non-branded marketing campaigns for Novartis (<US$10 000). RG reports non-financial support from Pfizer Australia, personal fees from Pfizer Australia, personal fees from Cornerstones, personal fees from Janssen New Zealand, non-financial support from Janssen Australia, personal fees from Novartis, outside the submitted work. JSH reports grants from Rheumatology Research Foundation, grants from Childhood Arthritis and Rheumatology Research Alliance (CARRA), personal fees from Novartis, outside the submitted work. ES reports non-financial support from Canadian Arthritis Patient Alliance, outside the submitted work. PS reports personal fees from American College of Rheumatology/Wiley Publishing, outside the submitted work. JY reports personal fees from AstraZeneca, personal fees from Eli Lilly, grants from Pfizer, outside the submitted work. PM reports personal fees from AbbVie, personal fees from Eli Lilly, personal fees from Novartis, personal fees from UCB, outside the submitted work. PR reports personal fees from AbbVie, non-financial support from BMS, personal fees from Eli Lilly, personal fees from Janssen, personal fees from Pfizer, personal fees from UCB, non-financial support from Roche, personal fees from Novartis, outside the submitted work. ZI, LJ, PK, SLT, SR, JFS, LT, KW, WC, JWL and ZSW have nothing to disclose.
Patient and public involvement Patients and/or the public were involved in the design, conduct, reporting or dissemination plans of this research. Refer to the 'Methods' section for further details.
Patient consent for publication Not required.
Ethics approval The C19-GRA physician registry was determined 'not human subjects research' by the UK Health Research Authority and the University of Manchester, as well as under United States Federal Guidelines assessed by the University of California, San Francisco and patient consent was not required.
Provenance and peer review Not commissioned; externally peer reviewed.
Data availability statement Request for access to data from the registry should be made to the Data Access and Sharing Committee of the COVID-19 Global Rheumatology Alliance.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.